UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2013
Biozone Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
333-146182
|
|
20-5978559
|
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ
|
|
07632
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (201) 608-5101
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.02. Unregistered Sales of Equity Securities
On December 19, 2013, Biozone Pharmaceuticals, Inc. issued 12,946,891 shares of common stock to six noteholders upon conversion of notes from $0.10 to $0.20 per share. As a result, all amounts due and outstanding under these notes have been satisfied. The securities were issued in reliance upon the exemption provided by Section 3(a)(9) under the Securities Act of 1933.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BioZone Pharmaceuticals, Inc.
|
Date: December 26, 2013
|
By: /s/ Elliot Maza
|
|
Name: Elliot Maza
Title: Chief Executive Officer and Chief Financial Officer